Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences. It is a structural analog of the immunomodulatory peptide tuftsin, with an additional three amino acid sequence (Pro-Gly-Pro) appended to the C-terminus to improve metabolic stability. Selank has been the subject of preclinical research across multiple domains, including neuroscience, immunology, and behavioral pharmacology.
Tuftsin Analog Design
Tuftsin is a naturally occurring tetrapeptide (Thr-Lys-Pro-Arg) derived from the enzymatic cleavage of the Fc region of immunoglobulin G. It was first characterized for its role in stimulating phagocytic activity of macrophages and monocytes. Selank extends the tuftsin sequence to Thr-Lys-Pro-Arg-Pro-Gly-Pro, where the Pro-Gly-Pro tail serves as a metabolic stabilizer by protecting the peptide from rapid degradation by aminopeptidases and carboxypeptidases in plasma.
This structural modification significantly extends the half-life of the peptide compared to native tuftsin, which is rapidly degraded in biological systems. The resulting heptapeptide retains the immunomodulatory properties of the parent sequence while exhibiting additional neuroactive properties that have been the focus of considerable preclinical investigation.
Anxiolytic Research in Animal Models
Selank has been extensively studied in rodent models of anxiety-like behavior, including the elevated plus maze, the open field test, and the light-dark box paradigm. In these preclinical behavioral assays, administration of Selank has been associated with anxiolytic-like effects, as measured by increased time spent in open arms, increased exploratory behavior, and reduced freezing responses. These behavioral outcomes have been reported across multiple laboratories and dosing regimens.
Mechanistic studies have investigated the neurochemical basis of these behavioral observations. Research has reported that Selank administration in animal models is associated with modulation of monoamine neurotransmitter metabolism, including alterations in serotonin, norepinephrine, and dopamine turnover in specific brain regions such as the hippocampus and hypothalamus. Additionally, studies have examined the effects of Selank on gamma-aminobutyric acid (GABA) receptor expression and function.
BDNF Modulation Research
Brain-derived neurotrophic factor (BDNF) is a critical neurotrophin involved in neuronal survival, synaptic plasticity, and memory formation. Several preclinical studies have investigated the effects of Selank on BDNF expression in rodent brain tissue. These studies have reported that Selank administration is associated with increased BDNF mRNA expression in the hippocampus, frontal cortex, and other brain regions in rodent models.
The relationship between Selank, BDNF expression, and behavioral outcomes has been a subject of particular interest. Researchers have hypothesized that the anxiolytic-like effects observed in animal models may be mediated, at least in part, through upregulation of BDNF-TrkB signaling pathways. However, the precise causal relationship between Selank administration, BDNF modulation, and behavioral changes remains an active area of investigation.
Immune Regulation Research
Consistent with its structural relationship to tuftsin, Selank has been investigated for immunomodulatory properties in preclinical models. In-vitro studies using isolated immune cell populations have reported that Selank can modulate cytokine expression profiles, including effects on interleukin-6, interferon-gamma, and tumor necrosis factor-alpha production. Animal studies have examined its effects on immune cell counts, phagocytic activity, and antibody production in response to immunological challenges.
These dual neuroactive and immunomodulatory properties have positioned Selank as a research tool for studying the neuroimmune interface, the bidirectional communication between the nervous system and the immune system. This is a growing field of preclinical investigation with implications for understanding how immune signaling affects neural function and vice versa.
Handling and Administration
Selank is supplied as a lyophilized powder and should be stored at negative twenty degrees Celsius. It is typically reconstituted in bacteriostatic water or sterile saline for research use. In animal studies, intranasal and subcutaneous administration routes have both been employed. Reconstituted solutions should be stored at two to eight degrees Celsius and used within two to three weeks. Researchers should verify purity by HPLC and confirm molecular identity by mass spectrometry using the Certificate of Analysis provided with each lot.
Research Use Statement
Selank is sold exclusively for in-vitro and preclinical research purposes. It is not intended for human consumption, veterinary use, or therapeutic application of any kind. The preclinical findings described in this article should not be interpreted as evidence of efficacy or safety in humans. Researchers must comply with all applicable regulations and institutional guidelines when working with this compound.